ACON News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AC

Volume

11.10K

Next Earnings

November 11th

Loading chart

AC

ACONAclarion, Inc. Common Stock

ACON

Pay with—

Available Balance0.00

AC

Mkt Cap

$5.6M

Volume

11.10K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentAclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.GlobeNewswire Inc. · Oct 8, 2026

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationAclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of its Nociscan platform and generate real-world evidence. The partnership will evaluate how Nociscan's chemical biomarker measurements work alongside SPECT-CT imaging to improve diagnostic precision for chronic low back pain treatment decisions.GlobeNewswire Inc. · Jun 3, 2026

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyAclarion's Nociscan MRS technology was used in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The research found that elevated propionic acid levels in lumbar discs can identify a subgroup of Modic type 1 patients with distinct immune activation, suggesting potential applications beyond surgical decision support for personalized spine care and immune-modulating therapies.GlobeNewswire Inc. · Jun 1, 2026

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanAclarion, Inc. announced the appointment of Daniel Keefe as Commercial Director for the Western U.S. to expand adoption of its Nociscan platform, a cloud-based diagnostic tool for identifying sources of chronic low back pain. The appointment reflects strong triple-digit growth in utilization and the company's strategic focus on deepening market presence in the Western region. Keefe brings over 20 years of medical device sales experience from companies including Zimmer Biomet and Intuitive Surgical.GlobeNewswire Inc. · Apr 28, 2026

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 CatalystsAclarion announced its 2026 strategic priorities including pursuing reimbursement coverage from regional US insurance providers, an initial CLARITY trial readout expected in Q4 2026, and maintaining a strong balance sheet with cash runway into 2028. The company continues expanding adoption of its Nociscan platform for identifying chronic low back pain sources.GlobeNewswire Inc. · Mar 19, 2026

Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance SheetAclarion, Inc. announced its participation in the 38th Annual ROTH Conference (March 22-24, 2026) where CEO Brent Ness will meet with institutional investors and analysts. The company highlighted its strong balance sheet with no debt and plans to expand adoption of Nociscan, its MR spectroscopy platform for identifying painful discs in chronic low back pain patients, in both the UK and US markets.GlobeNewswire Inc. · Mar 17, 2026

Aclarion CEO Brent Ness to Attend LSI USA 2026Aclarion, Inc. announced that CEO Brent Ness will attend LSI USA 2026 (March 16-20 in Dana Point, CA) to meet with investors and industry partners regarding the company's NOCISCAN platform. NOCISCAN is a proprietary MR spectroscopy platform using AI and biomarkers to help physicians identify painful discs in chronic low back pain patients.GlobeNewswire Inc. · Mar 12, 2026

Aclarion Publishes 2026 Shareholder Letter from the ChairmanAclarion, Inc. announced a strengthened financial position with cash runway extending into 2028, eliminating the need for capital raises before key clinical milestones. The company terminated its ATM and ELOC, reinforcing shareholder alignment. Aclarion expects an initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and public disclosure of early interim results in Q4 2026.GlobeNewswire Inc. · Feb 5, 2026

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence GenerationAclarion, Inc. announced an agreement with Source Healthcare, a Los Angeles-based orthopedic clinic, to expand availability of Nociscan and generate real-world evidence comparing the non-invasive diagnostic tool to anesthetic discography. The partnership supports Aclarion's growth strategy in the chronic low back pain market and aims to build clinical data for payer and provider adoption.GlobeNewswire Inc. · Feb 3, 2026

Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan RolloutAclarion (NASDAQ: ACON) raised $10.4 million through common stock financing at $5.18 per share, extending its cash runway into 2028 with zero debt and $21.6 million in cash. The company plans to accelerate clinical trials for its Nociscan AI platform, expand access across MRI platforms, and pursue broader reimbursement. Despite strong 2025 adoption metrics (69% YoY scan volume growth), the stock fell 5.21% to $4.27, trading at a new 52-week low.Benzinga · Jan 13, 2026

to start trading

AC

ACONAclarion, Inc. Common Stock

ACON

Pay with—

Available Balance0.00

Your PositionYou don't own any ACON yet.

Related Tickers

Earnings